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Cancer metastasis is the major cause of cancer-related deaths. Some proteins/lipids-attached 
glycans are aberrantly expressed in cancer and this pattern is highly associated with malignancy 
and tumor progression. Thus, aberrant glycans are promising candidates as cancer biomarkers 
and therapeutic targets. Glycosyltransferases overexpression is the main mechanism behind 
tumor-associated glycans such as Sialyl-Tn (STn), α2,6-sialyl lactosamines and Sialyl Lewis X 
(SLex) antigens. 
Colorectal cancer (CRC), the second most common cancer, is described to present STn and 
SLex, which correlate with disease progression. Although no glycan biomarkers yet reached 
clinical application due to the scarce understanding of the molecular mechanisms and the lack of 
relevant in vitro/vivo models to address them.  
Therefore, this study main goal was to establish experimental models of CRC cell lines expressing 
altered glycans and to evaluate their behavior in vitro through: CRC cell lines 1) overexpressing 
STn and 2) expressing Luciferase. In the first, the LS174T cell line was transduced with 
ST6GALNaC I gene to induce STn expression. In the second, SW48, SW948, SW620 and HT29 
cell lines that overexpressed, or not, relevant sialyl and fucosyltransferases were used: ST6Gal 
1 responsible for increased α2,6 sialylation; and FUT 6, responsible for increased SLex 
expression. These cell lines were then genetically modified to express LUCIFERASE (LUC) gene 
to allow cell tracking. 
After ST6GALNaC I or LUC genes transduction, the cells were phenotyped by flow cytometry to 
assess glycan expression and Luciferase was assessed by bioluminescence. Results showed 
that LS174T did not induce STn expression after transduction, since its precursor was absent. 
Regarding the remaining cell lines transduced with LUC, only HT29 FUT VI and SW948 ST6GAL 
I, and respective controls, emitted bioluminescence when tested.  
This study contributed to the comprehension of cancer-related glycan expression in CRC cell 
lines. These established cell lines may open the way for future investigation lines of metastasis 
development in vivo.                                                       
 













Metástases tumorais são a maior causa de mortes relacionados com cancro. Alguns glicanos, 
ligados a proteínas/lípidos, estão aberrantemente expressos em cancro e este padrão está 
altamente associado a malignidade e progressão tumoral. Assim, glicanos aberrantes tornam-se 
promissores candidatos para biomarcadores tumorais e alvos terapêuticos. A sobre expressão 
de dadas glicosiltransferases é o principal mecanismo adjacente a glicanos tumorais como é o 
caso dos antigénios Sialil-Tn (STn), α2,6-sialil lactosaminas e Sialil Lewis X (SLex). 
Cancro colorretal (CRC) é o segundo tipo de cancro mais comum e expressa STn e SLex, o que 
se correlaciona com progressão da doença. Apesar de nenhum dos glicanos propostos ter 
chegado ainda à clínica devido à falta de compreensão dos mecanismos moleculares adjacentes 
e de modelos in vitro e in vivo. 
Assim sendo, o principal objetivo deste estudo foi estabelecer modelos de linhas celulares de 
CRC que expressavam glicanos alterados e avaliar o seu comportamento in vitro por:  
estabelecer linhas de CRC que 1) sobre expressassem STn e 2) que expressassem Luciferase. 
Na primeira, a linha LS174T foi transduzida com o gene ST6GALNaC I de forma a induzir a 
expressão de STn. Na segunda, as linhas SW48, SW948, SW620 e HT29, a expressar ou não 
relevantes sialil e fucosiltransferases foram usadas; nomeadamente ST6Gal 1, responsável pelo 
aumento de α2,6-sialilação; e FUT 6, responsável pelo aumento de expressão de SLex. Estas 
linhas foram geneticamente modificadas para expressar o gene da LUCIFERASE (LUC) para 
permitir o seguimento celular por bioluminescência. 
Após transdução com os genes ST6GALNaC I ou LUC, as células foram fenotipadas por 
citometria de fluxo para aceder à expressão de glicanos e a expressão de Luciferase foi testada 
por bioluminescência. Os resultados mostraram que as LS174T, não expressavam STn após 
transdução, uma vez que o seu percursor estava ausente. Relativamente às restantes linhas 
quando transduzidas com LUC, só as HT29 FUT VI e SW948 ST6GAL I e respetivos controlos, 
emitiram bioluminescência.    
Este estudo contribuiu para a compreensão da expressão de glicanos-tumorais em linhas 
celulares de CRC. Estas linhas estabelecidas podem ter aberto o caminho para novas linhas de 
investigação para o desenvolvimento metastático in vivo. 
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1.1  Cancer 
Cancer is one of the most prevalent diseases and the second leading cause of death, worldwide. Such high 
incidence and its related mortality leads to the importance of an early and correct diagnosis and to the 
discovery of effective treatments, in order to cure or to improve the life quality and expectancy of cancer 
patients. Lung, liver, colorectal and breast cancers are the most deadly types of cancers, since their etiology 
is mostly related to dietary or behavioral risk factors1. 
This process occurs by normal cells transformation into malignant cells due to gene mutation that can lead to 
oncogene activation and/or tumor suppressor genes loss of function. These genetic alterations are the result 
of the combination of genetics and carcinogens exposition1. Cancer cells differ from normal cells by the 
acquisition of certain common capabilities during their development that allows them to survive, proliferate and 
differentiate in uncontrolled ways. These are called the Hallmarks of Cancer (Figure 1.1). Nowadays, ten 
common alterations have been described: self-sufficiency in growth signals, insensitivity to anti-growth signals, 
evasion from cell death signals, unlimited replication capacity, sustained angiogenesis and tissue invasion and 












According to the cell type from which the tumor arises, tumors are classified into carcinomas, which 
includes 90% of all cancer, if the primary cell is epithelial; sarcomas if the origin is in connective tissue; 
lymphomas for immune system cells; and leukemias for blood-forming cells. They are also classified 
according to their tissue of origin, for example,  adenocarcinoma have its origin in glandular tissue4.  
Figure 1.1 Hallmarks of Cancer. Adapted from Hanahan, 20113. 
 
 
Cancer cells can undergo an invasion process called metastasization. It originates with the loss of cell-
cell adhesion ability and it is defined as the tumor capacity to spread and invade from the primary site 
to adjacent healthy tissue and distant organs. This ability is the main cause of the increasing mortality 
ratio within cancer patients. While many early stage tumors can be treated with surgery or local 
irradiation, metastasized ones are more difficult to treat. Cancer cells have genetic instabilities and such 
heterogeneity that allows them to survive in unfavorable environments5. The molecular mechanism 
behind this process is still unknown, but already some genes and molecules known to be involved with 
it have been identified. The metastatic process consists of many steps where cells detach from the 
primary tumor, invade, circulate in the blood stream or in lymph, extravasate, are able to survive, 
proliferate, and promote angiogenesis6.  Although most of the cells that enter the circulation do not 
survive, others develop the ability to adhere the vascular walls in a host organ and extravasate. The 
adhesion to the extra-cellular matrix (ECM) is mediated by selectins and their respective ligands. Cancer 
cells can produce collagenase IV which degrades collagen IV, the main component of membranes. 
When this happens, an inflammatory response is created, and the recruitment of leukocytes and 
macrophages is initiated, allowing the extravasation and the permeabilization of the membranes/walls. 
Adhesion molecules such as laminin, fibronectin and collagen are essential for cancer cells to adhere 
to the endothelium membranes and to attach to basal lamina. It has been described that cell malignancy 
is associated with overexpression of adhesion molecules receptors, regulating adhesion and motility of 
these cells7. Metastasis have been shown to have preferred spreading sites as happens in bone, in  
breast and prostate cancers8. 
 
1.1.1  Colorectal Cancer  
Colorectal Cancer (CRC) is the second most common cause of cancer-related death in women and the 
third in men9. Its causes are various but mostly related with diet habits, prior family cases, age and 
untreated polyps. What makes this kind of cancer particularly dangerous is the presence of high genetic 
and molecular heterogeneity among its cells. This high incidence combined with an asynthomatic 
behaviour translates into an urgent need to develop prognostic tools and therapy methods in order to 
reduce and avoid disease progression. In fact, most patients with metastatic CRC have higher chances 
of recurrence, even after surgery and chemotherapeutic treatments.  
The majority of CRC are adenocarcinomas. They usually originate with a polyp in the colon or rectum 
that can, sometimes, develop into a tumor: in this scenario, preliminary detection  through colonoscopy 
becomes an essential prevention tool10. However, CRC can derive in metastic CRC within the liver and 
without proper biomarkers, it is very difficult to detect by endoscopy. 
 
1.2 Glycosylation 
All mammalian cells have on their surface a layer of sugars, the glycocalyx. Glycans have an important 
role in biological activities such as cell-cell interactions, cell-ECM interactions, differentiation, adhesion 
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together with motility, cell growth, immune response, amongst others11, since they are the first face of 
interaction regarding to cells.  
Glycosylation is the most common post-translational modification process in eukaryotic cells, where 
carbohydrate donors and carbohydrate acceptors react through enzyme mediation, to form chains that 
are linked to specific protein and lipid glycosites. Glycosyltransferases are the enzymes responsible for 
glycan biosynthesis and glycoconjugates formation using a single nucleotide-sugar as a donor 
substrate. This mainly occurs in the lumen of the Endoplasmic Reticulum (ER) and Golgi Apparatus, but 
also in the Cytoplasm and Plasma Membrane. On  other hand, glycosidases are the enzymes that are 
responsible for hydrolyzing some specific glycan linkages 12.   
There are a wide variety of glycans due to monosaccharide composition, branches, and different 
linkages. Therefore, a nomenclature was created, the Nomenclature Committee of the Consortium for 
Functional Glycomics (CFG), where glycans structures are represented as symbols and text (see 
Apendix I). 
Glycosylation can produce several types of glycoconjugates or glycans. From the five classes known, 
this thesis will only focus on two: O-glycans or N-glycans. N-glycosylation is the binding of a N-
acetylglucosamine (GlcNAc) residue to the amine group of an asparagine (Asn) residue of a protein side 
chain, especially to the motif Asn-X-Ser/Thr and O-glycosylation is the linkage of a N-
acetylgalactosamine (GlacNAc) residue to the oxygen atom of a subset of serines (Ser) and threonines 








O-glycosylation process steps occur in the trans-Golgi network by the linkage of monosaccharide units 
by the sequential action of glycosyltransferases. The position in the Golgi lumen, the level of expression 
and  the specificity of each of these enzymes determines the O-glycans patter13, being Tn is the simplest 
existing O-glycan. 
 
1.2.1 Sialic Acids 
Sialic acids (Sia or N-acetylneuraminic acid (Neu5Ac)) are the simplest monosaccharide family of the 
glycan chain of glycoproteins and glycolipids. Many cell surface glycoproteins and glycolipids can be 
Figure 1.2 N-linked (A) and O-linked (B) glycans representation. From Varki, 200911. 
 
 
modified by sialylation through the linkage of Sia. Due to their several α-linkage possibilities between its 
nine-carbon backbone, their diversity is vast. Usually they are situated at the terminal branches of N-
glycans, O-glycans and glycosphingolipids (Figure 1.3) and their negative charge center can be H-











Given their non-reducing terminal position in cell membranes, they have several important biological 
roles. They are related with various biological processes such as cell/cell interactions, B and T cell 
activation in the immune system and cell differentiation, maturation and they constitute the attachment 
site for pathogens. An altered sialylation is also implicated in tumorigenicity such as metastasis of 
malignant cells 14. 
 
1.2.2 Glycosyltransferases and Glycosidases 
The enzymes in charge for glycan biosynthesis are called glycosyltransferases and act by the sequential 
addiction of monosaccharides from a high-energy nucleotide sugar donor to specific positions on 
determined precursors, originating linear or branched sugar chains. Most are found in the ER/Golgi 
pathway15.  
Glycosidases are responsible for the degradation of sugar chains. These may be endo or 
exoglycosidases and their action is correlated with low pH levels. Exoglycosidases act by cleaving the 
linkage of terminal carbohydrates from the nonreducing end. On other hand, endoglycosidases cleave 
internal glycosidic linkages of larger chains that can later be degraded by exoglycosidases15.   
 
1.2.2.1 Sialyltransferases and Sialidases  
Sialyltransferases are the glycosyltransferase family responsible for adding CMP-activated Sia residues 
to specific terminal non-reducing positions on oligosaccharides of proteins or lipids.  The substrates can 
A 
Figure 1.3 Sialic acids structure and position in the terminal branches of N-glycans, O-glycans and 
glycosphingolipids at cell surface. A) Usual position of sialic acids. Adapted from Pinho, 201549  B) Structure 




be galactose residues (Gal), GalNAc or Sia. These enzymes are type II membrane proteins from the 
Golgi apparatus, therefore, Sia are added during glycoproteins biosynthesis.   
The sialyltransferase enzyme family vary according to their tissue distribution and to the Sia linkage that 
they form. Sia can be added by some of them, such as: ST3Gal 1 sialyltransferase in α2,3 linkage to 
galactose; ST6Gal 1 sialyltransferase in α2,6 linkage to galactose or by ST6GalNAc to N-
acetylgalactosamine; or by the α2,8 linkage by a family of polysialyltransferases to other Sia. The 
aberrant expression of these enzymes is highly correlated with cancer. For the aims of this thesis only 
ST6Gal 1 and ST6GalNAc 1 are going to be considered.  
ST6GAL I gene is present in chromosome 3 in humans and in chromosome 4 in mice and codes for 
ST6Gal 1 enzyme. This enzyme is a type II membrane protein, but it can also be found in the soluble 
form. It is highly expressed in lymphocytes and hepatocytes where it is the mainly responsible for 
catalyzing α2,6 sialylation of membrane glycoproteins and of serum glycoproteins, respectively, on N-
glycan cases 11.  
ST6GalNAc 1 is the human enzyme responsible for adding Sia in α2,6 linkage to O-linked GalNAc 
residues linked to a Ser or Thr, leading to Sialyl-Tn antigen (STn) a cancer related antigen that is one 
of the main incidences on this work.  
Sialidases or neuraminidases are the enzymes responsible for catalyzing the cleavage of the Sia from 
glycans: they have been described as having an important role in the pathogenesis of diseases16, since 
they can be found in lysosomes and endosomes that degrade glycoproteins.  
 
1.2.2.2 Fucosyltransferases 
Fucosyltransferases (FUT) are a glycosyltransferase family that transfer a fucose residue from a 
guanosine diphosphate fucose (GDP-fucose) donor to glycoconjugate acceptors. Human FUT genes 
can be divided into α1,2-FUT, α1,3/4-FUT and α1,6-FUT. The first family is the responsible for blood 
group antigens, such as ABO, and Lewis y (Ley). In the second family, we have From FUT 5 to FUT 7 
and from FUT 9 to FUT 11. One of them, FUT6 is responsible for Lewis x (Lex) and Sialyl-Lewisx (SLex) 
biosynthesis17, another important cancer related antigens that this thesis is going to refer to. 
 
1.3 Glycosylation and Cancer  
Due to their importance in several biological aspects, the glycans are also expressed during crucial 
steps of tumor progression and metastasis development in aberrant forms, increasing tumor 
malignancy18. Cancer cells exhibit a high variety of altered glycosylation cell surface patterns such as 
loss or overexpression of structures such as complex N-glycans and incomplete or truncate O-glycans, 
accumulation of precursors and novel structures, all modifications that are absent or diminished in 
normal healthy cells15. These altered carbohydrate structures are named tumor-associated 
carbohydrate antigens (TACAs). TACAs can be divided in two categories: glycoprotein antigens and 
glycolipid antigens19. This can be the result of an abnormal expression and activity of 
 
 
glycosyltransferases or glycosidases or also due to their deallocated position in the Golgi Apparatus as 


















Figure 1.4 Tumor associated carbohydrate antigens structure in normal mammalian cell surface 
mucins and in tumor cells surface. In normal healthy cells, the glycosylation pattern is more elaborated that 
in cancer cells. Adapted from Roy, 2013 51. 
Figure 1.5 Cancer associated glycans. A) N-glycans are covalently bound do Asn residues of protein membranes, 
with two or more branches, associated with tumor invasion; B) O-linked glycans are covalently bounded to Ser/Thr 
residues of glycoproteins or mucins, as SLex/a that are overexpressed in cancer-cell mucins; STn and Tn are tumor 
antigens correlated with invasion, that are truncated forms of O-glycans; C) Glycosphingolipds are sugar linked to 
the lipidic layer of cell membranes that includes some sialilated structures associated with tumor growth: GM3, GM1, 
GD2 and GD3; D) Glycosylphosphatidylinositol (GPI)-linked proteins are anchored to the membrane by a glycan 
covalently linked to a phosphatidylinositol. Glycosaminoglycans can also appear as free chains (E); F) 
Proteoglycans can be related with cell-growth activation and cell adhesion; G) O-linked N-acetylglucosamine (O-
GlcNac) can be associated with cytoplasmic or nuclear proteins and can even be released to the extracellular 
matrix. (Glc – glucose, Gal – galactose, Man – mannose, GlcNAc - N-acetylglucosamine, GalNAc - N-




Aberrant glycosylation leads to, consequentially, altered cell/cell and cell/matrix interactions which can 
explain some abnormality of tumor cells such as unlimited growth, tumor invasion and metastatic 
potential22 that combined with absence in normal cells, make glycans good biomarkers for diagnosis, 
prognosis and therapy. Some studies already correlate the high level of some truncated O-glycans with 
low rates of survival in cancer patients23,24. Sialylated structures of Thomsen-Friedenreich (TF) antigens 
are also examples of truncated glycans. Many of these glycans are already used in clinical practice and 
are related to immune system escape, attachment to capillaries in tumor invasion and new adhesion in 
metastasis. This aberrant glycosylation can be detected in blood tests since some of these are present 
in the serum18. 
α2,6-sialyltransferases have been shown to be upregulated in some tumor cells. ST6Gal I 
overexpression has already been described in several carcinomas, such as colon, and some studies 
indicate its upregulation is due to oncogenes activation such as RAS. The high activity of this enzyme 
is correlated with a poor prognosis and metastasis25.  The same has been described for ST6GalNAc 1 
enzyme, since it overexpression is the mainly responsible for STn formation and upregulation, a cancer 
related antigen that has been found in several carcinoma types and that is associated with poor 
prognosis and metastasis development26. 
 
1.3.1 Thomsen-Friedenreich Antigens 
TF antigens or disaccharides Galβ1-3GalNAcα1-Ser/Thr or T antigens, are the core 1 structure of O-
linked mucins, thus being present in membrane glycoproteins. They are truncated in the early stages of 
glycosylation27 and have been correlated with tumor progression and metastases and also the natural 
human production of antibodies against them is very low in cancer patients27. Cancer cells can lose the 
ability to synthetize core 1 and in that case, the Tn antigen, GalNAc α1-Ser/Thr, is exposed which is 
also a carcinoma correlated antigen that occurs in approximately 90% of human cancers. Lastly, Tn can 









Figure 1.6 Thomsen-Friedenreich Antigens biosynthesis pathway. After the linkage of GalNac to a Ser/Thr 
residue, Tn antigen can be converted to core 1 structure, T antigen, and further in core 2, in normal cells. In cancer 
cells, Sialyl-Tn antigen can be produced due to core 1 synthesis inability. Adapted from Pavão, 201152. 
 
 
1.3.2 Sialyl-Tn Antigen 
STn (Neu5Acα2-6GalNAcα-O-Ser/Thr or CD175s) is a truncated O-glycan antigen used as an epithelial 
cancer biomarker. It has been used not only for diagnosis and prognosis, but also for immunotherapy 
targeting since it is not found in healthy tissue. It is the simplest sialylated mucin-type O-glycan and it is 
composed by a GalNAc residue α-O-linked to a Ser or Thr residue in a protein that is sialilated on carbon 
6. 
The sialylation of a single O-GalNAc has been shown to be performed in vitro by two sialyltransferases, 
ST6GalNAc 1 and ST6GalNAc 2 28. However, studies using transfected cells by either one of these 
enzymes has demonstrated that in a cellular context, only ST6GalNAc 1 overexpression generates STn 
structures recognized by anti-STn antibodies29,26,30. It can be associated with a variety of membrane 
proteins such as mucins, integrins and CD44. 
It is expressed in almost all carcinomas and in nearly 80% of CRC. STn expression is associated with 
oncogenesis and the metastatic ability of cancer cells, being therefore correlated with poor prognosis in 
cancer patients.  
 
1.4 Study of glycans in vitro and Luciferase enzyme 
To track cancer cells in vivo and in vitro, the Luciferase enzyme (LUC) can be overexpressed in cells 
and then used as a reporter. Luciferase is an enzyme that efficiently catalyzes light production through 
a chemical reaction, present in bioluminescent living organisms. The chemical reaction requires 
luciferin, Mg2+ and O2 as co-factors, and, in case of insects, also ATP31. Through cDNA cloning, the 
LUCIFERASE gene can be introduced into the cancer cells genome by transduction and further 
expressed. It is widely used as a reporter gene and the detection assay is very sensitive one32. Its 
detection can be assessed by direct bioluminescence, alternatively, the cells need to be lysate for the 
enzyme to be approachable.  
Firefly luciferase has a wide potential and applicability since it has no endogenous activity in the choose 
host cells, is able to be detected by a reproducible assay and the protein does not need posttranslational 
modifications.  
In this thesis work, the LUCIFERASE gene was cloned in a lentiviral vector and this was transduced 
into CRC cell lines to be further tracked in living organisms, making sure that this genetic modification 
in the CRC cell lines did not change their glycan expression either way.  
 
1.5 Introduction to the aims of this thesis 
Since metastasis is the major cancer related cause of death, it is extremely important to uncover the 
molecular mechanism behind metastasis formation and development as a basis to their prevention. 




CRC cells can produce mucin glycoproteins with O-linked oligosaccharides that have been found to 
express TF antigens. Tn and STn antigens, both examples of these, shown to be highly sensitive and 
specific tumor-associated antigens in the colon that are absent in normal colon tissue33, making them 
potential biomarkers. Also, the SLeX antigen is another highly expressed glycan in solid tumors, that 
have potential as biomarker. This aberrant glycosylation is associated with a poor prognosis, cancer 
progression and metastasis development.  
STn is expressed when over or incomplete synthesis of α2,6-sialylation occurs due to ST6GalNAc 1 
overexpression and it has been found in 80% of human carcinomas such as colon adenocarcinomas 
and that is associated with a poor prognosis35,20. Moreover, SLex provide ligands for selectin adhesion 
receptors on activated endothelia, platelets or leukocytes what are thought to be involved in metastasis 
extravasation and its presence is due to the overexpression of fucosyltransferase FUT 636. ST6Gal 1 
expression is upregulated in several carcinomas being CRC among them. 
In this study, the main goal was to establish experimental genetically modified models based on CRC 
cell lines expressing both altered glycans and Luciferase reporter. To achive this, the work consisted in 
two arms. 
In the first part, we aimed to establish a CRC cell line overexpressing the STn antigen. To assess this, 
the LS174T cell line was transduced with the ST6GALNaC I gene. This transduced cell lines were 
phenotyped to assess the expression of STn antigen. Since this cell line naturally express high levels 
of other relevant glycans, namely the SLex, but not of STn, it was expected to obtain a CRC cell line that 
had a dual overexpression of STn and SLex/a antigens. This cell line could also be used in further 
transduction experiments to overexpress the LUC gene. However, after several attempts to transduce 
the cell line with lentivirus containing the ST6GALNaC I gene, it was not possible in this work to obtain 
the desired LS174T cell line overexpressing STn. Further studies are necessary to understand the 
mechanism behind these results.  
In the second part, we establish CRC cell lines expressing LUC enzyme. We used the SW48, SW948, 
SW620 and HT29 CRC cell lines that were previously transduced and transfected with sialyl and 
fucosyltransferases to express relevant altered glycans. Namely the ST6Gal 1 sialyltransferase, 
responsible for increased α2,6 sialylation, and the FUT 6 fucosyltransferase, responsible for increased 
SLex expression, respectively.  These cell lines were posteriorly genetically modified to express the 
reporter LUC gene through transduction with pLenti6/V5 directional TOPOvector, containing the LUC 
cDNA. Luciferase expression was tested by bioluminescence and the cell lines were characterized in 
terms of glycosylation profiles, comparing them with their negative control (NC) or MOCK cell lines, 










2 Materials and Methods 
 
2.1 Culture of Colorectal Cancer Cell Lines  
Several colorectal cancer (CRC) cell lines were used during this work: SW620, LS174T SW48, SW948 
and HT29. All CRC cell lines were kindly provided by Professor FABIO DALL’OLIO from the University of 
Bologna, Italy. As controls, another cell lines were used, MDA and HEK293 Star cells. All of them had 
the three variants – the wild type (WT); the empty vector (EV) or MOCK or negative control (NC); and 
FUT VI or ST6GAL I or STn positive cell lines.   
SW620 (ATCC®CCL-227TM) cell line derived from a Dukes’ type C metastatic adenocarcinoma from 
colon in lymph node from a 51-year-old Caucasian male. LS174T (ATCC®CL-188TM) cell line was 
established from Dukes’ type B adenocarcinoma of colon from a 58-year-old Caucasian female. SW48 
(ATCC®CCL-231TM) derived from Dukes’ type C, grade IV, adenocarcinoma of colon from an 82-year-
old Caucasian female. SW948 (ATCC®CCL-237TM) was established from Dukes’ type C, grade III, 
adenocarcinoma of colon from an 81-year-old Caucasian female. HT29 (ATCC®HTB-38TM) derived from 
an adenocarcinoma of colon from a 44-year-old Caucasian female.  
The used CRC cell lines were adherent and were kept in T25 and T75 culture flasks (SARSTEDT), in a 
37°C incubator (Panasonic) with a humidified atmosphere and 5% CO₂ .The culture media used was 
dependent on the cell line: SW48, SW948 and SW620 cell lines were cultured in Leibowitz’s medium 
(Lonza) supplemented with 10% of Fetal Bovine Serum (FBS) (Gibco), 2mM of L-glutamine (Gibco) and 
100 µg/mL Penicillin/Streptomycin (Gibco); LS174T were cultured in MEM (Biowest) supplemented with 
10% FBS (Gibco), 2Mm L-glutamine (Gibco), 100 µg/mL Penicillin/Streptomycin (Gibco), Non-Essential 
Aminoacids (Gibco) and Sodium Pyruvate (Gibco); HT29 and MDA cell lines were cultured with DMEM 
(Gibco) supplemented with 10% de FBS (Gibco), 2mM of L-glutamine (Gibco) and 100 µg/ml 
Penicillin/Streptomycin (Gibco). The medium was changed every three days. For passages, at 80/90% 
of confluency, the culture was washed with 1X phosphate buffered saline (PBS) and 1X Trypsin-EDTA 
(TE) (Gibco) was used for cell detachment from the flask, followed by a centrifugation (Eppendorf) step 
at 200xg for 5 minutes and cultured according to the desired dilution. All cell lines were stored at -80°C 
resuspended in culture medium and 10% (v/v) o dimethyl sulfoxide (DMSO) (Sigma). 
 
2.2  Techniques  
 
2.2.1 Transduction 
Transduction is a gene transfer mechanism through viral infection of host cells that allows genome 
integration and the consequent expression of the gene of interest. In this thesis work, the viral vector 
used was a lentiviral one.  
To construct it, a three-plasmid system was used that contemplates a lentiviral construct with the cDNA 
sequence of interest, an expression vector with the vesicular stomatitis virus G envelope glycoprotein 
 
 
gene (VSV-G) and a packing vector. They also have present truncated long-terminal residues (LTR) for 
self-inactivation37. The coding reagion of human ST6GALNaC I gene was before amplified by PCR and 
cloned in the pLenti6/V5 Directional TOPO cloning vector containing the CMV promoter, as well for 
LUCIFERASE. Lentiviral particles were generated by co-transfection of HEK 293 T cells with the three 
plasmids, using pPACK Lentivector Packing Systems, what was kindly performed by Professor Doutor 









2.2.2 Flow Cytometry 
Flow Cytometry analyzes single particles in suspension such as cells, while they flow in a fluid, through 
a light beam, usually a laser. It is a technique that is able to measure simultaneously particle size, 
complexity, and fluorescence intensity. These characteristics are determined by how the particle 
scatters light since its structural complexity scatters light at different angles and quantities. When 
particles are stained with a fluorophore, the incidence laser excites this molecule making it emit light 
with a certain wavelength. The fluorescent emitted light is detected, filtered, and amplified to be 
converted into digital data by a flow cytometer. A flow cytometer allows the determination of the median 
fluorescence intensity (MFI) or percentage of positive cells that are proportional to the amount of 
antibody bonded that is proportional to the amount of expressed antigen.  
Forward-scattered light (FSC) is proportional to the relative size and area of the particle since scatter at 
lower angles. Side-scattered light (SSC) is proportional to the cell complexity or granularity, as scatters 
at larger angles. The correlation of these two measurements leads to a differential population analysis 
through their physical characteristics. 
When a fluorochrome is conjugated with an antibody that recognizes specific receptors, it can be used 
to detect a cell type according to the antigen at its surface.  
The particle characteristics are determined by an optic-electronic system that registers how the particles 
disperses light and emits fluorescence. Flow Cytometry its formed by three systems: fluidics, that leads 
the particles to the laser beam; the optic system that its composed by the laser beam and the optic filters 
that direct the light signals to the proper detectors; and the electronics, that processes the light signals 
into electronic signals38,39. 
Figure 2.1 Three plasmid packing system. Adapted from System Bio, 53 
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The Flow Cytometer used in this work was an Attune® Acoustic Focusing Cytometer (Applied 
Biosystems) with two lasers, red (638nm) and blue (488nm) that allows up to six different fluorescence’s, 
four for blue laser (BL1: green, BL2: orange, BL3: red and BL4: red) and two for the red laser (RL1: light 
red and RL2: dark red).  
At least 1x104 events were acquired in the Attune Cytometric Software (version 2.1) and all data was 
analyzed in FlowJo (version10) and GraphPad Prism (version7). Upon the flow cytometry acquisition, 












2.2.3 Fluorescence Microscopy  
Fluorescence Microscopy is an optical microscopy type that uses fluorescence to generate an image by 
enlarging the optic resolution and the contrast of the microscopy image. The image is created using an 
opening, the pinhole, that allows a better definition to be obtained in thicker samples. 
A laser is focused in the limited place for diffraction in the sample from the objective. The emitted 
fluorescence is focused by the same lens to a specific point in the detector. The pinhole is then placed 
at this point such that the detector only captures the light prevenient from the focal plane. By plotting 





















Marker of interest 
Figure 2.2 Gating strategy for flow cytometry acquisitions. The scheme characterizes the gating steps upon 
flow cytometry data acquisition. After cell suspension aspiration, the density plot graph FSC-A vs SSC-A on the left 
is generated and then the gate (indicated in black) is drawn to cover the cell population within 10 000 events. This 
gate is used to generate a histogram graph of fluorescence channel vs count where the positive cells peak is 
counted from the end of the unstained peak. At this point the MFI or % of positive cells is extrapolated. 
 
 
The microscope used was a Axiolmager D2 – Zeiss, with a 40x objective and the laser filters of 488 nm 
and 633 nm to excite FITC and Alexa Fluor 633, respectively. The images obtained were processed by 
Fiji.  
 
2.2.4  Real Time Polymerase Chain Reaction 
The Real Time Polymerase Chain Reaction (RT-PCR) is an enzymatic process that converts RNA into 
its complementary DNA (cDNA) by reverse transcriptase enzyme action, followed by cDNA amplification 
by PCR41. It is a very powerful and sensitive tool to analyze and quantify the expression of a gene by 
mRNA expression. In this thesis, TaqMan technology was used. TaqMan probes are oligonucleotide 
hydrolysis probes that are dually labelled with a fluorophore linked to the 5’ end with a non-fluorescent 
quencher linked to the other end of the probe. When closer, the quencher reduces the fluorescence 
emitted by the fluorophore but with the presence of the target sequence, the probe hydrolysis with it and 
the exonuclease activity of Taq DNA polymerase, degrades the probe annealed to the target sequence, 
emitting fluorescence that is detected by the device. This fluorescence emitted is proportional to the 
amplification42. 
Quantification is performed by relative quantification where the change of expression of the target gene 
is described by comparison with the expression of an endogenous control gene. The ideal reference 
gene should have a stable and secure expression regardless of the conditions in which it is used, since 
they are vital to cell survival. In this thesis two housekeeping genes were used, GAPDH (that codes for 
glyceraldehyde-3-phosphate dehydrogenase) and β-actin. The relative expression was analyzed using 
the comparative CT mathematical method, 2-ΔΔCT method, from Livak and Schmittgen43. CT stands for 
Threshold Cycle and corresponds to the intersection of the amplification curve with the threshold line. 
The threshold fluorescence is defined according to the point at which the fluorescence rises significantly 
above the background fluorescence level. ΔCT corresponds to the variation between the amplification 
value of the gene of interest and the endogenous control gene, so ΔΔCT will correspond to the variation 
between the amplification values of the gene of interest and the variation between all the controls 
amplification44. Therefore, 2-ΔΔCT, will correspond to the amount of target when normalized with the 
reference. 
 
2.2.5  Luciferase Detection Assay 
Luciferase is an oxidoreductase enzyme capable of catalyzing light production in living organisms, 
bioluminescence, through a chemical reaction of luciferin oxidation that can act as a genetic reporter. 
Luciferin oxidation and an electron transition, form oxyluciferin. Firefly luciferase cDNA is a 1,6kb 
fragment that codes for 550 aminoacid residues and a 61kDa protein. The enzymatic reaction requires 
the cofactors luciferin, ATP, Mg2+ and O245. Bioluminescence is a special kind of chemiluminescence 
present in living organisms that is transformed to visible light. Firefly luciferase emits a yellow-green light 







The luciferase assay offers a nearly instantaneous measure of total luciferase expression in the lysate; 
therefore, the emitted light is proportional to the luciferase concentration. Although the high efficiency of 
the assay, the luciferase half-life is less than three hours due to it low intrinsic stability, as a 
disadvantage. 
 
2.3 Colorectal Cancer Cell Lines Characterization 
 
2.3.1 Transduction Protocol 
Before transduction itself, 5x105 cells per well in a 12 well plate, were seeded. The next day, the virus 
were thawed at room temperature in a concentration of 150 µL of virus to a concentration of 8 µg/ml of 
polybrene in 2 ml of medium. The cells were washed with 1X PBS and this mixture was placed in the 
wells. The plate was shaken and incubated overnight, 37º, 5% CO2. The next day the cells were washed 
again and the new culture medium was placed with 3,2 µg/ml of Blasticidin. This selection process was 
performed during approximately two weeks since the plasmid inside the virus had the resistance to 
Blasticidin antibiotic and the cells that did not incorporate the plasmid, would die.  
 
2.3.2 Cell Phenotype Analysis by Flow Cytometry 
 
2.3.2.1  Flow Cytometry Protocol 
Cancer cells were detached with TE from the culture flasks and washed with 1X PBS by centrifugation 
at 200xg, for 5 minutes. The resultant pellet was resuspended in 1ml of medium and the cells were 
counted in a 1:10 dilution in a Newbauer chamber (Marienfeld). 2x105 to 3x105 cells per condition were 
collected in a centrifuge tube and washed again. At this point, we could proceed to a direct antibody 
staining or to a sialidase treatment as described forward. The desired concentration of cells was then 
washed with 500 µl of PBS 1X and centrifuged at 1500xg for 2 minutes. The supernatant was discarded 
and the previous step was repeated but with 990 µl of 1X PBS. The pellets were resuspended in the 
desired volume of 1X PBS to be divided as 100 µl per condition. The primary antibodies were added 
and the samples were incubated at 4ºC for 30 minutes. Another wash step was performed with 500 µl 
of 1X PBS and centrifuged at 1500xg for 2 minutes. The supernatant was discarded and the pellets 
were resuspended in 100 µl of 1X PBS. The secondary antibody was added according to the primary 




antibody used and the samples were incubated at room temperature for 15 minutes in the dark. At the 
end of this step the cells were again washed with 500 µl of 1X PBS by centrifugation at 1500xg for 2 
minutes. The supernatant was discarded, and the pellets were resuspended in 1 ml of 1X PBS to by 
analyzed by Flow Cytometry. If required, the cells were fixed in 4% Paraformaldehyde (PFA) to be 
analyzed later.  
 
2.3.2.2  Sialidase Treatment Protocol 
The sialidase treatment was performed to remove the sialic acid from structures according to the 
experimental case, once it had hydrolyses the α2-6 and α2-3 sialic acid linkage. After the first wash, the 
supernatant was discarded, and the cells were resuspended in 400 µl of sialidase buffer. This 400µl of 
cell suspension was divided between two eppendorf tubes, a sialidase treated one and a non-treated, 
control. For the sialidase treated one, sialidase (from Clostridium perfringes, Roche) was added at a 
final concentration of 100 mU/ml. Both samples were incubated at 37ºC, 5% CO2 for 90 minutes during 
which time, the tubes were stirred to avoid cell deposition.    
 
2.3.2.3  Cell Lines Staining with Antibodies 
To assess glycans expression at the cell surface, a flow cytometry assay was performed. The primary 
antibodies used and their correspondent amounts, and the secondary antibody and respective amount 
and fluorescence method used are detailed in Table 2.1.  
 
Table 2.1 Antibody description table. Primary antibodies list, correspondent antigens and secondary antibodies, 
quantities used and fluorescence, used in cancer expressing glycans screening. 
Primary 
Antibody 
Antigens Amount Secondary 
Antibody 
Amount Fluorochrome 
B72.3 STn 1,5 µL Goat anti-mouse 
(Dako) 
5 µL FITC 
5F4  
 
Tn 8 µL Goat anti-mouse 
(Dako) 
5 µL FITC 
A70-C/C8 Lewis y 5 µL Goat anti-mouse 
(Dako) 
5 µL FITC 
CD15 
(Biolegend) 
Lewis x 2 µL Goat anti-mouse 
(Dako) 
5 µL FITC 
CD15s 
(BD Biosciences) 
SLex 3 µL Goat anti-mouse 
(Dako) 
5 µL FITC 
antiCD44-APC  
(Biolegend) 
CD44 5 µL _ _ APC 
HECA-452 SLex/a 1,5 µL Goat anti-rat 1 µL APC 
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(Biolegend) (BD Pharmingen) 
CA19.9 
(Abcam) 
SLea 5 µL Goat anti-mouse 
(Dako) 
















2.3.3 Cell Phenotype Analysis by Fluorescence Microscopy 
 
2.3.3.1  Fluorescence Microscopy Protocol  
0,4 x 106 cells/mL of LS174T WT, LS174T ST6GALNaC I and 0,2 x106 cells/mL of MDA STn cells were 
cultured on top of round coverslips inside 12 well plates (Orange Scientific). After 24h, they were washed 
three times with 1X PBS for 5 minutes. They were then fixed and permeabilized with 200µl of wash 
solution (Fixation/Permeabilization Solution Kit from BD Biosciences) for 20 minutes at 4ºC. In order to 
be labeled with the anti-ST6GALNaC I antibody (2C3 clone), the cells were incubated with 1 ml of wash 
solution for 30 minutes and then washed three times with 1X PBS for 5 minutes. The incubation with the 
primary antibody anti- ST6GALNaC I labeled with Cy5, occurred during 30 minutes at a dilution of 1:2 
in wash solution. Cells were then washed three times with 1X PBS for 5 minutes. To stain the nucleus, 
To-Pro3-Alexa Fluor 633 (Invitrogen) was used by covering the cells for 15 minutes and then washed 
three times with 1X PBS, 5 minutes. Finally, the coverslip was placed face down on the slide, and sealed 
with montage medium Mowiol (Dabco) and nail polish to be analyzed in the Fluorescence Microscope.  
 
2.3.4 Gene Expression Analysis of ST6GALNACI by RT-PCR 
 
2.3.4.1 RT-PCR Protocol 
The first step of the RT-PCR protocol was the RNA extraction using GenEluateTM Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich). A lysis solution/2-ME was previously prepared with 10 µL of 2-
Mercaptoethanol (Sigma) to 1 ml of lysis solution and the centrifuge was set at 4ºC. Cells were 
trypsinyzed and centrifuged at 0,4xg for 5 minutes and washed with 1X PBS. 250 µL of lysis solution/2-
ME was added to approximately 5x106 cells and pipetted until no clumps were present. The cell lysate 
was then collected to a filtration column into a 2ml tube and centrifuged at 12000xg for 2 minutes. The 
filtration column was discarded and into the resulting lysate was added 250 µL of 70% ethanol and the 
resulting solution mixed. Up to 700ml of the lysate/ethanol mixture was pipetted into a binding column 
in a 2ml tube and centrifuged at 12000xg for 2 minutes. The flow-through liquid was discarded but the 
collection tube was kept to repeat the previous step if the volume was more than 700ml. 250 µL of wash 
solution 1 was added to the column and centrifuged at 12000xg for 2 minutes. To the mix, 10 µl of 
 
 
DNase I (Quiagen) were added with 70 µL of digestion buffer (Quiagen) by inversion. From this mixture 
80 µL were then added into the filter of the binding column and incubated at room temperature for 15 
minutes. 250 µL of wash solution 1 was pipetted into the column, centrifuged at 12000xg for 2 minutes 
and the flow-through was discarded. The washing step was repeated twice but with 500 µL of wash 
solution 2. The biding column, now empty, was again centrifuged at 12000xg for 2 minutes because of 
the remaining liquid and transferred into a new 2ml collection tube. To this, 55µL of elution solution was 
pipetted into the binding column and centrifuged at 12000xg for 2 minutes. The flow-through was again 
passed through the column and centrifuged at 12000xg for 2 minutes since the purified RNA was then 
in the flow through liquid.  
The RNA conversion to cDNA was performed using a High-Capacity cDNA Reverse Transcription Kit 
as described in the following table.  
 
Table 2.2 Conversion mix content and respective amounts (µL) 
Components Amounts (µL) 




Reverse transcriptase enzyme 7,5 
RNase free H2O 18,5 
 
The thermocycler machine used was a Programmable Thermal Controller PTC-100TM (MJ Research, 
Inc.) and it was set according to the settings listed in table 2.3. After the cDNA conversion, the samples 
could be stored at -20ºC.   
 
Table 2.3 Settings of the used program to cDNA conversion 
 Step 1 Step 2 Step 3 Step 4 
Temperature (ºC) 25 37 85 4 
Time 10 min 120 min 5 secs ∞ 
 





Table 2.4 RT-PCR mix content and respective amounts 
Components Amounts (µL) 
Diluted probe 1:4 2 
cDNA 2 
RNase free H20 1 
Master Mix Fast (Applied Biosystems) 5 
 
Each experiment was performed in duplicates and using two endogenous controls. The probe of interest 
was ST6GALNACI (Applied Biosystems) and the endogenous were GAPDH (Applied Biosystems) and 
β-actin (Applied Biosystems). The samples were runned in RotorGene 6000 (Corbett) machine 
according to table 2.5 and the results were analyzed has previously described followed by GraphPad 
Prism 7 (GraphPad Software, Inc). 
 
Table 2.5 Conditions for RT-PCR assay 
 Step 1 (1 cycle) Step 2 (40-50 cycles) 
Temperature (ºC) 95 95 60 
Time 20 secs 3 secs 30 secs 
 
2.3.5  Luciferase Expression Assessment 
SW48 MOCK and SW48 ST6GAL I, SW948 MOCK and ST6GAL I, SW620 MOCK and SW620 FUT VI 
and HT29 MOCK and HT29 FUT VI were transduced with the lentiviral vector pLenti6/V5-D-TOPO 
containing luciferase gene from firefly that codes for luciferase enzyme, originating SW48 MOCK LUC, 
SW48 ST6GAL I LUC, SW948 MOCK LUC, SW948 ST6GAL I LUC, SW620 MOCK LUC, SW620 FUT 
VI LUC, HT29 MOCK LUC and HT29 FUT VI LUC. 
 
2.3.5.1  Luciferase Detection Assay Protocol 
To assess luciferase expression, a Luciferase Assay System Kit (Promega) was used. This kit can 
improve the kinetics of the chemical reaction to enhance the light intensity created after reaction by 
incorporating coenzyme A (CoA). 
24 hours before the detection assay, 105 cells per well were cultured in a 96 well plate. The following 
day, the medium was removed, and the cells were washed with 1X PBS. 20 µl of 1X lysis buffer RLB 
from the kit was added to each well and a single freeze-thaw cycle was performed to ensure the 
complete lysis. At room temperature, 100µl of luciferase assay reagent were added, composed by 
luciferase assay buffer and luciferase assay substrate and the samples were read at Chemidoc Touch 




2.3.5.2  Colony Picking for SW48 and SW948 Cell Lines 
The luciferase enzyme used for transduction in this thesis was isolated from firefly (Photinus pyralis). 
SW948 MOCK, SW948 ST6GAL I, SW48 MOCK and SW48 ST6GAL I had to be selected by a colony 
picking method and not by the usual antibiotic one, since they were previously transduced with a plasmid 
with the same antibiotic resistance. 
To performed it, the cell cultures were kept growing until they could form visible and isolated colonies. 
Twenty-four colonies were then picked by small papers imbibed in trypsin that would detach them. These 
colonies were cultured in 24 well plates (Greiner Bio-One Cellstar) and then tested to check for 
















2.3.6  Cell Growth Curves 
To establish cell growth curves of each cell line, a first culture with 80/90% confluency was counted in 
a Neubauer Chamber (Marienfeld) at 1:2 dilution with trypan blue and ten T25 flasks were cultured with 
the initial number of 20000 cells/ml each. The medium was changed every five days and every day for 
10 days, at the same hour, one flask was tripsinyzed and the number of cells were counted as explained 
above, using a Neubauer Chamber. The curves were then constructed using the Log10 value and 
analyzed in Excel (Microsoft). 
Figure 2.4 Colony selection and detection protocol. In the scheme above, the colony picking protocol is 
described. First, some filter paper was cut in small pieces and autoclaved, to only cover one big colony each. The 
second part consists in soak them with trypsin-EDTA. In the third, each piece of paper is placed on top of a big 
isolated colony for it to attach to the paper. In the fourth, on a 24 well plate, each selected colony is placed in a well 
along with the respective paper. The next step was to analyze chemiluminescence for each colony, through the 
result observed in the sixth phase. 
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A typical growth curve for cultured cells should have a sigmoid pattern of proliferation and the growth 
phases associated are defined as: Lag Phase, an adaptation period in which cells do not divide; Log 
Phase, where the cells are more active in proliferation and have an exponential increase of cell density; 
Plateau Phase, where proliferation slows due to confluency; and Decline Phase, where cells start dying 











2.4  Statistical Analysis 
Experimental data was analyzed using GraphPad Prism 7. Statistical differences were determined using 











Figure 2.5 Cell Growth Graph. Cell growth curve with the respective phases of growth. In the yy axis is the Log 







In this work, we aimed to develop colorectal cancer (CRC) cell line models overexpressing both aberrant 
glycans and Luciferase to be used in tracking assays.  For that purpose, CRC cells expressing aberrant 
glycans were established through overexpression of glycosyltransferases involved in the glycan 
biosynthesis and, transduced with LUCIFERASE (LUC) gene. These CRC cell line models can be used 
to assess the impact of glycan overexpression in cell functions and the bioluminescence produced by 
Luciferase enzyme can be used to track cells in vitro an in vivo. In this work, we were able to assess 
cell phenotype of a set of CRC cell lines. In the future, the cell line models here developed can be used 
to follow and evaluate tumor formation, proliferation, and metastasis development in living organisms.  
In particular, the project was developed in two separated parts presented in the following sections. The 
first part described in section 3.1 had a specific aim to establish a CRC cell line overexpressing the 
sialyl-Tn (STn) antigen. The work in this section thus consisted on the genetical medication of a CRC 
cell line that did not expressed STn, the LS174T cell line, by transducing it with the ST6GALNaC I gene. 
This transduced cell line was phenotyped to assess the expression of STn antigen.  
The second part, described in section 3.2, had a specific role to establish CRC cell lines expressing the 
Luciferase enzyme. The work in this section, thus consisted on the genetical modification of several 
aberrant glycan expressing CRC cell lines, with the LUC gene. The resulting transduced cells were then 
phenotyped to assess their glyosidic profile together with Luciferase activity. 
Table 3.1  Summary table for the used cell lines 
















HT29 FUT VI 
 










SW620 FUT VI 
 







3.1  Establishment of a CRC cell line overexpressing STn Antigen  
As mentioned before, in this part of the study, we aimed to establish a CRC cell line overexpressing the 
STn antigen. To asses this, the LS174T cell line was transduced with the ST6GALNaC I gene, a flow 
cytometry was performed using the mouse anti-STn antibody, B72.3, as described on section 2.3.1.1. 
The STn antigen was expected to be expressed in the ST6GALNaC I transduced LS174T cells and on 
MDA STn+ cells, a previous transduced cell line expressing STn used as positive control. Although the 
results observed were the expected for MDA STn+ cells, with a 67,9% of expression (presented in red 
in the graph below), LS174T ST6GALNac I did not show any STn expression at cell surface, since only 
2,08% of the population were positive for the fluorescence read. 
 
The ST6GALNaC I expression in the transduced cell lines was assessed using a Real Time Polymerase 
Chain Reaction (RT-PCR). The expression in the LS174T cell lines transduced or not with ST6GALNaC 
I gene was compared in between and also with a positive control, the breast cancer cell line, MDA STn+. 
As shown in Figure 3.2, through RT-PCR, the expression of ST6GALNaC I in the LS174T ST6GALNaC 
I transduced cell line was very low, 72,42. As expected, the positive control MDA STn+ cell line showed 
a positive expression and, the negative control, LS174T WT cell line showed a negative expression. 
A B 
Figure 3.1 STn assessment by flow cytometry in MDA STn and LS174T ST6GalNaC I cell lines. On the 
histograms, the yy axis represents the number of cells and the xx axis represents the fluorescence intensity 
on the BL1-A channel. A) MDA STn+ unstained cells (blue), MDA STn+ cells with secondary antibody 
staining (orange) and MDA STn+ cells stained with B72.3 (red); B) LS174T ST6GALNaC I unstained cells 
(blue), LS174T ST6GalNaC I cells with secondary antibody staining (orange) and LS174T ST6GalNaC I 












No STn expression does not necessarily have to be associated with ST6GalNAc 1 absence. Therefore, 
ST6GalNAc 1 presence was assessed. This assay was performed by Fluorescence Microscopy using 
an anti- ST6GalNAc 1 antibody that was recognized by a secondary, Cy5. ST6GalNAc 1 expression 
was observed in the Fluorescence Microscopy images on LS174T ST6GALNaC I transduced cells as 
presented above, by a red fluorescence around the cell nucleus (on green), being concordant with the 
Golgi Apparatus localization, where the glycosyltransferases are located. The controls used were 
LS174T WT variant with no red fluorescence and LS174T ST6GALNaC I stained with the secondary 










At this point the presence of the STn precursor had to be controlled and another flow cytometry was 
performed, using sialidase treatment to remove the sialic acid and uncover the Tn antigen. For this, the 
anti-Tn antibody used was 5F4. The results showed an absent expression of Tn on LS174T WT and 
LS174T ST6GALNaC I transduced cells, explaining why STn cannot be present in these cells, although 
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ST6GALNACI  
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Nuclei – ToPro3 
ST6GalNAc 1 – Cy5 
Nuclei – ToPro3 
ST6GalNAc 1 – Cy5 
Nuclei – ToPro3 
ST6GalNAc 1 – Cy5 
T WT LS174T ST6GALNaC I IIAb LS174T ST6GALNaC I anti-ST6GalNAc 1  
A B C 
Figure 3.2 ST6GALNaC I Expression Assessment by RT-PCR. In the presented graph is shown the relative 
mRNA levels of the ST6GALNaC I gene. The yy axis represents the relative mRNA levels and the xx axis the cell 
line in study. 
Figure 3.3 Fluorescence microscopy images of LS174T.  On image A the negative control LS174T WT variant is 
presented, on image B there is LS174T ST6GALNACI transduced cells stained with just secondary antibody and on 
C there is LS174T ST6GALNaC I cells stained with anti-ST6GALNaC I antibody.  In the three images, the nuclei 














Figure 3.4 STn and Tn assessment by flow cytometry in LS174T WT and LS174T ST6GALNaC I cell lines 
with and without sialidade treatment. On the histograms, the yy axis represents the number of cells and the 
xx axis represents the fluorescence intensity on the BL1-A channel. A) LS174T WT cells with sialidase treatment: 
unstained cells (red), with secondary antibody staining (blue), with B72.3 staining (orange) and with 5F4 staining 
(green); B) LS174T WT cells with no sialidase treatment: unstained cells (red), with secondary antibody staining 
(blue), with B72.3 staining (orange) and with 5F4 staining (green); C) LS174T ST6GALNaC I cells with sialidase 
treatment: unstained cells (red), with secondary antibody staining (blue), with B72.3 staining (orange) and with 
5F4 staining (green). D) LS174T ST6GALNaC I cells with no sialidase treatment: unstained cells (red), with 
secondary antibody staining (blue), with B72.3 staining (orange) and with 5F4 staining (green). 
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To check the cell line transduction efficiency, the transduction was repeated in HEK293 Star, a cell 
line well known to be efficiently transdusable and the results observed were slightly positive for 






3.2  Luciferase Expression and Luciferase Cell Lines Characterization 
After lentiviral transduction with LUCIFERASE gene and transduced cells respective selection methods, 
SW948 MOCK LUC, SW948 ST6GAL I LUC, SW48 MOCK LUC, SW48 ST6GAL I LUC, SW620 MOCK 
LUC, SW620 FUT VI LUC and HT29 MOCK LUC and HT29 FUT VI LUC cell lines were tested for 




Figure 3.5 STn and Tn assessment by flow cytometry in HEK293 Star and LS174T ST6GALNaC I cell lines 
with and without sialidade treatment. On the histograms, the yy axis represents the number of cells and the xx 
axis represents the fluorescence intensity on the BL1-A channel. A) HEK293 ST6GALNaC I cells with sialidase 
treatment: unstained cells (red), with secondary antibody staining (blue), with B72.3 staining (orange) and with 3F1 
staining (green); B) HEK293 ST6GALNaC I cells with no sialidase treatment: unstained cells (red), with secondary 
antibody staining (blue), with B72.3 staining (orange) and with 5F4 staining (green); C) LS174T ST6GALNACI cells 
with sialidase treatment: unstained cells (red), with secondary antibody staining (blue), with B72.3 staining (orange) 
and with 5F4 staining (green). D) LS174T ST6GALNACI cells with no sialidase treatment: unstained cells (red), 
with secondary antibody staining (blue), with B72.3 staining (orange) and with 5F4 staining (green) 
 
 
lysates were tested in Chemidoc with a 50 seconds exposition period in a 96 well plate where the cells 
were cultured the previous day in a concentration of 105 cells. As bioluminescence baseline control, a 
well with only luciferin reagent was added for each assay. 
3.2.1  SW948 MOCK LUC Cell Line 
In SW948 MOCK LUC cell line, from twenty-four isolated colonies, only four were positive for luciferase 
what was observed by a higher bioluminescence emission as shown in figure 3.6. After two weeks in 









It was also necessary to confirm that Luciferase expression in the cells did not interfer with some tumour 
associated glycans that our research group is interetsed in. To assess it, the CRC cell lines SW948 
MOCK expressing or not the LUC gene were phenotyped by flow cytometry using several antibodies 
reactive against glycans. For this purpose, the B72.3 antibody was used to assess STn, the CA19.9 
antibody was used to asses SLea, the CD15s to assess SLex, CD15 to assess Lex, anti-Lewis Y to 
assess Lewis Y,  the 5F4 antibody to assess Tn, and the HECA-452 to assess SLex/a. Two proteins 
known to be potentially carriers of theses glycans were also analysed, namely CD44 and the 
carcinoembryonic antigen, using the appropriate antibodies. No significant differences were observed 
when comparing SW948 MOCK and SW948 MOCK LUC cells as observed in the histograms above. 
HECA-452 and anti-CD44 stainings manteined their expression as expected. 
CTRL
s 
SW948 MOCK LUC Lysates   
SW948 MOCK LUC Lysates   
Figure 3.6 Luciferase expression in SW948 MOCK LUC transduced cells in a 96 well plate analized by 
Chemidoc. 96 well plate bioluminescence from SW948 MOCK LUC cell lysates from transduced cells with LUC 
gene. From well A1 to well B12, there were 24 different isolated colonies lysates from SW948 MOCK LUC cell line 
with luciferin reagent. The C1 well had SW948 MOCK LUC  lysate without luciferin reagent, C2 had SW948 MOCK 






Two ten-day cell growth curves, along with the correspondent photo report was also carried out to 
compare both cell lines in terms of proliferation rates and confluency. The point correspondent to Day 2 
show a higher number of cells/mL in SW948 MOCK LUC cell growth curve, in comparison to SW948 




Figure 3.7 Glycan expression assessment by flow cytometry in SW948 MOCK and SW948 MOCK LUC cell 
lines. On the histograms, the yy axis represents the number of cells and the xx axis represents the fluorescence 
intensity on the BL1-A channel on the right and on RL1-A channel on the left. A) SW948 MOCK cells: unstained cells 
(red), with secondary antibody staining (blue), with B72.3 staining (orange), with CA19.9 staining ( light green), with 
CD15s staining (dark green), with CD15 staining (light purple), with anti-CEA staining (purple), with anti-Lewis Y 
staining (dark blue) and with 5F4 staining (yellow); B) SW948 MOCK cells: unstained cells (red), with secondary 
antibody staining (blue), with HECA-452 staining (orange) and with anti-CD44 staining (green); C) SW948 MOCK 
LUC cells: unstained cells (red), with secondary antibody staining (blue), with B72.3 staining (orange), with CA19.9 
staining ( light green), with CD15s staining (dark green), with CD15 staining (light purple), with anti-CEA staining 
(purple), with anti-Lewis Y staining (dark blue) and with 5F4 staining (yellow); D) SW948 MOCK LUC cells: unstained 






































































Figure 3.8 Cell Growth Curve Graphs from SW948 MOCK and SW948 MOCK LUC cell lines. The yy axis 
corresponds to the Log10 of cell/mL and the xx axis corresponds to days.  The first graph describes the cell growth 
curve of SW948 MOCK converted. The second graph describes the cell growth curve of SW948 MOCK LUC. 
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Table 3.2 Cell Morphology During Prolonged Culture. Table shows microscope images comparing the 
confluency and cell morphology in two cell lines the SW948 MOCK and SW948 MOCK LUC. The left columns 


























































3.2.2 SW620 MOCK, SW620 FUT VI, HT29 MOCK, HT29 FUT VI, SW948 ST6GAL I, SW48 MOCK 
and SW48 ST6GAL I Cell lines  
For all the remaining cell lines, the same luciferase expression analysis was performed. For SW620 
MOCK and SW620 FUT VI LUCIFERASE transduced, no expression was observed. To SW48 MOCK 
and SW48 ST6GAL I LUCIFERASE transduced, the same absence of Luciferase expression was 
observed. Despite these negative results, eight isolated colonies from SW948 ST6GAL I LUC, HT29 
MOCK LUC and HT29 FUT VI LUC were positive for luciferase expression as presented on image 3.9. 
From SW948 ST6GAL I LUC the chosen colonies were those correspondent to wells G8, G9, H1, H8, 
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Figure 3.9 Luciferase expression in HT29 MOCK LUC, HT29 FUT VI LUC and SW948 ST6GAL I LUC 
transdcuced cells in a 96 well plate analized by Chemidoc. 96 well plate bioluminescence from HT29 MOCK 
LUC, HT29 FUT VI LUC and SW948 ST6GAL I LUC cell lysates from transduced cells with LUC gene. Wells A1 
and A2 had HT29 MOCK LUC cell lysates duplicates with luciferin reagent and A3 had HT29 MOCK LUC lysates 
without luciferin reagent. B1 and B2  wells had  HT20 FUT VI LUC cell lysates duplicates with luciferin reagent and 
B3 had HT29 FUT VI LUC cell lysates without luciferin reagent. The C1 well had contained only luciferin reagent. 
Well F1 had SW948 ST6GAL I LUC cell lysates without luciferin reagent, well F2 had only luciferin reagente and 































4 Discussion of Results  
Abnormal glycosylation is a hallmark of cancer and is often due to the overexpression of 
glycosyltransferases involved in the glycan biosynthesis. Several glycans have already been described 
in the literature as overexpressed in colorectal cancer (CRC) and are associated with growth, cell-
adhesion, migration, and proliferation of tumor cells. SLex and STn are examples of TACAs, that are 
overexpressed in carcinoma cells and that are highly related with poor prognosis and low survival of 
cancer patients.  
The CRC cells are an example of cancer cells that can be decorated with this cell surface antigens thus 
improving its malignancy. SLex and SLea expression at the cell surface of CRC cells, have been found 
to be associated with disease progression. In fact, higher expression levels of SLex appears to occur in 
more metastatic colorectal carcinomas that in the less metastatic. Likewise, STn have been described 
to induce oncogenic features in cancer cells such as proliferation, migration and invasion, and, therefore 
increasing metastasis formation20. 
For the reasons exposed above, in this thesis, we tried to develop a group of colorectal cancer cell 
models expressing some of the more relevant cancer associated glycans and study their development 
in vivo and in vitro to better comprehend how tumors migrate and metastize in the presence of these 
aberrant glycans. 
To have a consistent starting point of colorectal cancer cell lines expressing the chosen TACAs, we 
were missing a STn expressing cell line. For this reason, this thesis project was divided into two parts 
both based on aberrant glycans expression by colorectal cancer cell lines. The first part consisted on 
genetically modifying a non-expressing STn colorectal cancer cell line, LS174T, to express STn by 
transduction with the gene of the responsible enzyme for STn synthesis, ST6GALNaC I. The second 
part was based on luciferase expression, to be used as a tracing mechanism by SW48, SW948, SW620 
and HT29 CRC cell lines, already expressing tumor associated glycans by previous transduction and 
transfection with ST6GAL I and FUT VI genes, respectively, to evaluate tumor progression and 
metastasis formation through bioluminescence emission in vitro and in vivo.  
Since overexpression of STn has been reported in several epithelial cancers, with colorectal cancer 
among them47, and its expression is also associated with a poor prognosis and low patient survival, one 
of this work main goals was to lead to this antigen expression, for the study of metastasis formation and 
tumor proliferation due to its presence. The colorectal cancer cell line used was LS174T, since it has no 
STn expression.  On the contrary of the expected, LS174T cell line transduction with ST6GALNaC I 
gene did not lead to STn antigen expression. Although the transduction worked in LS174T and in 
HEK293 cell lines, and a small expression of ST6GALNaC I was observed on LS174T ST6GALNaC I 
at an early stage, by Fluorescence Microscopy and by RT-PCR, the remaining assays to detect STn 
expression were not as successful (Chapter 3.1). This may have been due to several reasons, but, when 
the STn precursor, Tn, was assessed, Tn was absent as well, justifying why STn was not being 
produced, although ST6GalNAc 1 expression was observed. Even though the cause of this specific 
result is explained, the reason why Tn is not being expressed by this cell line is not well understood and 
its comprehension requires the study of all steps of the Tn synthesis pathway. Nevertheless, some 
 
 
studies have determined that Tn formation is performed by T-synthase an enzyme controlled by a 
chaperone, Cosmc. Acquired mutations on the gene responsible for this chaperone codification, leads 
to a decrease on T-synthase activity and consequently lack of Tn and STn expression48.  
Regarding the second part of the project, as expected, SW948 MOCK transduced with the 
LUCIFERASE gene, expressed Luciferase by bioluminescence detection and maintained the same 
glycosidic profiles before, meaning that Luciferase expression by these cells, did not interfere with the 
cell line basal glycan expression levels. Concerning the growth rates between both cell lines, a 
difference was observed in the second day of the cell growth curve of the Luciferase expressing cell 
line, since it had a higher cell count. This may be due to counting errors or due to a more abrupt growth 
during log phase in the presence of Luciferase. 
Relative to the other described CRC cell lines, only HT29 MOCK LUC, HT29 FUT VI LUC and SW948 
ST6GAL I LUC were positives for Luciferase expression after transduction so, SW620 MOCK LUC, 
SW620 FUT VI LUC, SW48 MOCK LUC and SW48 ST6GAL I LUC were negative for bioluminescence 
production. This may be due to an unsuccessful transduction either due to the need of more selection 
time with antibiotic or a higher antibiotic concentration on SW620 cells and due to selection of the non-
expressing colonies in case of SW48 cells. Another reason this may have happened, lays on the need 
to use a higher Multiplicity of Infection (MOI) for this cell lines or to concentrate more the virus solution. 
MOI indicates the number of vector particles needed, for cell, in the transduction process for the optimal 
transduction efficiency and must be determined by the number of viral particles divided by the number 
of cells seeded, that may have been too low to the cells in study. Concerning the glycan profile and 
proliferation study assays for the Luciferase expressing cell lines HT29 MOCK LUC, HT29 FUT VI LUC 
and SW948 ST6GAL I LUC, these experiments deferred, due to time restrictions, likewise the repetition 
















































5 Conclusion and Future perspectives 
Cancer is one of the most prevalent diseases worldwide and metastasis are the major cause of cancer 
related deaths. Some carbohydrates are aberrantly expressed in cancer cells and this altered 
glycosylation pattern is highly associated with cancer malignancy, tumor progression and migration 
making tumor associated carbohydrates (TACA), promising candidates as novel cancer biomarkers and 
therapeutic targets. The upregulation of the enzymes responsible for their biosynthesis, namely the 
glycosyltransferases, is the main mechanism behind their overexpression. The Sialyl-Tn (STn) has 
gained particular interest as a cancer specific glycan, that has absent or minimal expression in normal 
healthy cells. Colorectal cancer (CRC) also shows an altered glycosylation pattern, associated with STn, 
but also with other TACAs such as the Sialyl Lewis X (SLex). Although this correlation is known, none 
of the proposed glycan biomarkers have already reached clinical application. This can be ascribed to 
the limited understanding of the molecular mechanisms and the lack of relevant in vitro and in vivo 
models to address them.  
Therefore, the main goal of this study was to establish experimental genetic models based on CRC cell 
lines expressing altered glycans and to evaluate their behavior in vitro and in vivo. To assess it, several 
CRC cell lines were analyzed:  SW48, SW948, SW620 and HT29, expressing relevant glycans by 
previous transduction and transfection with sialyl and fucosyltransferases, ST6GAL I and FUT VI. These 
cell lines were then transduced with the LUCIFERASE gene to enable cell tracking by bioluminescence 
emission. Additionally, CRC cell line LS174T was also used to conduct to STn antigen expression by 
transduction with ST6GALNaC I gene. In this last experiment, no expression of STn was obtained due 
to Tn precursor absence in this cell line. Regarding the Luciferase expression assays, half of the 
predicted cell lines expressed Luciferase after transduction, but the other half did not, which may be due 
to transduction ineffectiveness, what need to be repeated. Between SW948 MOCK and SW948 MOCK 
LUC, no significant differences were observed concerning glycans expression and growth rates. 
In the future, the remaining assays to conclude the luciferase cell lines characterization should be 
addressed and the initial project of using these cell lines and evaluate their migration and proliferation 
in vitro and in vivo should proceed, to better understand the metastasis development process in 
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Appendix 1: Symbol and Text Nomenclature for Representation of Glycan Structures 
(as selected by the Nomenclature Committee Consortium of Functional Glycomics, based on a version 
originally put forth by Stuart Kornfeld and later adapted by the editors of the textbook Essentials of 
Glycobiology (Cold Spring Harbor Laboratory Press) 
Symbol nomenclature must be convenient for the annotation of mass spectra. To this end, it was 
decided that: 
• Each sugar type (i.e. sugars of the same mass: hexose, hexosamine and N-acetylhexosamine), 
should have the same symbol shape. 
• Isomers of each sugar type (e.g. mannose/galactose/glucose) should be differentiated by color or 
by black/white/shading. 
• Where possible, the same color or shading should be used for derivatives of hexose (e.g. the 
corresponding N-acetylhexosamine and hexosamine). 
• Representing different sugars using the same shape but different orientation should be avoided so 
that structures can be represented either horizontally or vertically. 
Colored symbols should still appear distinguishable when copied or printed in black and white. 
Considering 10% of the population is color blind, the use of both red and green for the same shaped 
symbols should be avoided. 
When desired, linkage information can be represented in text next to a line connecting the symbols 
(e.g. alpha4, beta4). 





The Nomenclature Committee recommends a 'modified IUPAC condensed' text nomenclature which 
includes the anomeric carbon but not the parentheses, and which can be written in either a linear or 
2D version: 
▪ Including the anomeric carbon is important, and is likely to become increasingly more so in the 
future as more complicated structures are discovered. 
▪ The presence of parentheses (which then necessitates the use of brackets to indicate 
branching structures) is unnecessarily cumbersome, particularly when representing the 





















Figure 7.2 Text nomenclature adopted for glycan stuctures, both linear and 2D. Adapted from 
Nomenclature Committee Consortium of Functional Glycomics  54 
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Appendix 2: Composition of the solutions and reagents used in the work developed 
 
Complete DMEM culture medium: Simple DMEM supplemented with 10% (v/v) FBS, 2 mM L-
glutamine, 100 U/ml of penicillin and 100 μg/ml of streptomycin  
 
 
PBS 1x: Solution containing 1.47 mM of KH2PO4, 4.29 mM of Na2HPO4.7H2O, 137 mM of NaCl and 
2.68 mM of KCl, in distilled water (pH=7.4)  
 

























































Appendix 4: Abstract submitted to XLI Jornada da Genética  
 
Genetic cell models to assess the role of colorectal cancer-associated glycans  
 
C. Amaral1†, R. Zoppi2†, F. Deschepper3, J. Ramalho4, P. Videira5  
1,2,3,5 UCIBIO, Department of Life Sciences, Faculdade de Ciências e Tecnologia da Universidade Nova de 
Lisboa, Portugal  
4CEDOC, Nova Medical School from Universidade Nova de Lisboa, Portugal  
†Both authors contributed equally to this work  
 
Cancer is one of the most prevalent diseases worldwide and its metastasization is a major cause of 
cancer related deaths. Some carbohydrates attached to proteins or lipids, i.e. glycans, are aberrantly 
expressed in cancer cells and this altered glycosylation pattern is highly associated with cancer 
malignancy and tumor progression what makes them promising candidates as novel cancer biomarkers 
and therapeutic targets. Overexpression of certain glycosyltransferases (e.g. sialyltransferases and 
fucosyltransferases) is the main mechanism behind tumor associated glycans1. Our group is especially 
interested in the role of sTn, Tn, sLex, sLea and Ley antigens as cancer specific glycans, with absent 
or minimal expression in normal cells2.  
Colorectal cancer (CRC) is the second most common cancer type and it is also correlated with an altered 
glycosylation pattern. Although this correlation is well known, none of the proposed glycan biomarkers 
has already reached clinical application. This can be ascribed to the scarce understanding of the 
molecular mechanisms and the lack of relevant in vitro and in vivo models to address them.  
Therefore, the main goal of this study is to establish experimental models based on CRC cell lines 
expressing altered glycans and to evaluate their behavior in vitro and in vivo.  
To assess it, we analyzed CRC cell lines, SW48, SW948, SW620 and HT29 that express relevant 
glycans and that were previously transfected and transduced with sialyl and fucosyltransferases, the 
ST6GalI responsible for increased alpha 2-6 sialylation, and FUT VI responsible for increased sialyl 
Lewis X/A/Y expression. These cell lines were genetically modified to express luciferase (LUC) gene as 
a tracking mechanism by bioluminescence.  
After a successful transduction with pLenti6/V5 directional TOPOvector containing the luc gene and 
blasticidin selection, the luciferase expression was tested by bioluminescence and the cell lines were 
characterized in terms of glycosylation profiles, comparing them with their negative controls, MOCK cell 
lines, once previous studies showed that there is no difference between MOCK and WT.  
At present, we are analyzing tumor growth of the newly transduced cells lines. In the future progression 
and metastasis formation in animal models, will be also assessed. 
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